All Phenotypes Tg(Krt18-EGFP,-TAg121)36Ysng MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Tg(Krt18-EGFP,-TAg121)36Ysng
transgene insertion 36, Yurong Song
MGI:5449063

Summary

6 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Tg(Krt18-EGFP,-TAg121)36Ysng/0	involves: C57BL/6 * DBA/2	MGI:5617493
cn2	Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	MGI:5617494
cn3	Brca1^tm1Brn/Brca1^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	MGI:5617496
cn4	Brca2^tm1Brn/Brca2^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	MGI:5617497
cn5	Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N	MGI:5617495
cn6	Brca1^tm1Brn/Brca1^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N	MGI:5617499

Allelic Composition	Tg(Krt18-EGFP,-TAg121)36Ysng/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

abnormal ovary morphology ( J:189304 )

• when cre-expressing adenovirus is introduced under the bursa, 72% of ovaries exhibit cytologic abnormalities in the ovarian surface epithelium

ovary hyperplasia ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop minimal to mild atypical hyperplasia with occasional papillary epithelial projections 3 to 24 months postinduction

increased ovary tumor incidence ( J:189304 )

• mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium proliferation with progression only to stage I of ovarian cancer

increased ovarian carcinoma incidence ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium carcinoma in situ with no invasion into the underlying ovary or overlying bursa

• 18% of mice injected with cre-expressing adenovirus under the bursa exhibit ovarian tumors that progress to serous epithelial ovarian cancer pathology with early invasion into ovary and bursa

reproductive system

abnormal ovary morphology ( J:189304 )

• when cre-expressing adenovirus is introduced under the bursa, 72% of ovaries exhibit cytologic abnormalities in the ovarian surface epithelium

ovary hyperplasia ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop minimal to mild atypical hyperplasia with occasional papillary epithelial projections 3 to 24 months postinduction

increased ovary tumor incidence ( J:189304 )

• mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium proliferation with progression only to stage I of ovarian cancer

increased ovarian carcinoma incidence ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium carcinoma in situ with no invasion into the underlying ovary or overlying bursa

• 18% of mice injected with cre-expressing adenovirus under the bursa exhibit ovarian tumors that progress to serous epithelial ovarian cancer pathology with early invasion into ovary and bursa

neoplasm

increased ovary tumor incidence ( J:189304 )

• mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium proliferation with progression only to stage I of ovarian cancer

increased ovarian carcinoma incidence ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop ovarian surface epithelium carcinoma in situ with no invasion into the underlying ovary or overlying bursa

• 18% of mice injected with cre-expressing adenovirus under the bursa exhibit ovarian tumors that progress to serous epithelial ovarian cancer pathology with early invasion into ovary and bursa

growth/size/body

ovary hyperplasia ( J:189304 )

• 27% of mice injected with cre-expressing adenovirus under the bursa develop minimal to mild atypical hyperplasia with occasional papillary epithelial projections 3 to 24 months postinduction

Allelic Composition	Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (239 available)
Trp53^tm2Tyj mutation (4 available); any Trp53 mutation (239 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased ovary tumor incidence ( J:189304 )

• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system

increased ovary tumor incidence ( J:189304 )

• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Allelic Composition	Brca1^tm1Brn/Brca1^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1^tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (239 available)
Trp53^tm2Tyj mutation (4 available); any Trp53 mutation (239 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased ovary tumor incidence ( J:189304 )

• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology

increased ovarian carcinoma incidence ( J:189304 )

• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated

• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs

increased metastatic potential ( J:189304 )

• distant metastases are seen in the pleura of 87.5%, in the lung of 83% and in the liver of 46% of mutants intrabursally injected with Ad-cre that develop stage IV disease

increased carcinoma incidence ( J:189304 )

• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma

reproductive system

increased ovary tumor incidence ( J:189304 )

• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology

increased ovarian carcinoma incidence ( J:189304 )

• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs

abnormal oviduct morphology ( J:189304 )

• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma

• oviduct lesions are characterized by a glandular/acinar histology

homeostasis/metabolism

hemorrhagic ascites ( J:189304 )

• ovaries in intrabursally Ad-cre injected mice show hemorrhagic or serous ascites

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology

increased ovarian carcinoma incidence ( J:189304 )

• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Allelic Composition	Brca2^tm1Brn/Brca2^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca2^tm1Brn mutation (5 available); any Brca2 mutation (132 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (239 available)
Trp53^tm2Tyj mutation (4 available); any Trp53 mutation (239 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased ovary tumor incidence ( J:189304 )

• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system

increased ovary tumor incidence ( J:189304 )

• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Allelic Composition	Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (239 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased ovary tumor incidence ( J:189304 )

• 88% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

• 88% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system

increased ovary tumor incidence ( J:189304 )

• 88% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Allelic Composition	Brca1^tm1Brn/Brca1^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased ovary tumor incidence ( J:189304 )

• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system

increased ovary tumor incidence ( J:189304 )

• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 10/29/2024 MGI 6.24